Givinostat Market Summary

Key Factors Driving Givinostat Growth

1. First approved non-steroidal therapy for all genetic variants of DMD:

In March 2024, the U.S. FDA approved DUVYZAT® (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged ≥6 years, regardless of the underlying dystrophin mutation. It is the first non-steroidal and non-mutation-specific therapy approved for DMD, allowing treatment of a broad patient population unlike exon-skipping therapies that are limited to specific genetic mutations. This broad label significantly expands its commercial opportunity.

2. Compelling Phase III efficacy demonstrating slowed disease progression:

Approval was supported by the pivotal EPIDYS Phase III trial, which enrolled 120 ambulant boys receiving background corticosteroids. Givinostat significantly slowed the decline in physical function over 18 months, including a smaller deterioration in the North Star Ambulatory Assessment (NSAA) and reduced progression of muscle pathology compared with placebo. These clinically meaningful outcomes have strengthened physician confidence and support increasing uptake in neuromuscular centers.

3. Long-term evidence supports durable clinical benefit:

Extension studies with average follow-up exceeding 36 months, and some patients treated for more than eight years, demonstrated sustained slowing of disease progression and preservation of key motor functions while maintaining a favorable safety profile. These long-term data, published in peer-reviewed literature and presented at scientific meetings, reinforce the rationale for initiating therapy early and continuing treatment chronically, supporting long-term market growth.

4. Differentiated mechanism enables combination therapy potential:

Givinostat is a histone deacetylase (HDAC) inhibitor that reduces inflammation, fibrosis, and fatty replacement while promoting muscle regeneration. Because it acts independently of the dystrophin mutation, it can potentially be used alongside corticosteroids and mutation-specific therapies, including exon-skipping agents and selected gene therapies. This complementary mechanism increases its potential utilization across the DMD treatment landscape rather than competing directly with genotype-specific products.

5. Expanding real-world evidence and international commercialization:

ITF Therapeutics and Italfarmaco continue to generate health-economic and patient-reported outcome data showing that givinostat slows deterioration in daily activities and preserves functional abilities. These data are expected to support reimbursement negotiations and broader adoption in international markets, while additional regulatory reviews outside the U.S. continue to expand the drug's commercial footprint.

Givinostat Recent Developments

In July 2026, JCR Pharmaceuticals announced its development plan in Japan for Givinostat, a treatment for Duchenne muscular dystrophy (DMD), following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA).

“Givinostat Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Givinostat for approved indication like Duchenne muscular dystrophy; as well as potential indication like Polycythaemia vera and Myeloproliferative disorders in the 7MM. A detailed picture of Givinostat’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Givinostat for approved and potential indications. The Givinostat market report provides insights about Givinostat’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Givinostat performance, future market assessments inclusive of the Givinostat market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Givinostat sales forecasts, along with factors driving its market.

Givinostat Drug Summary

Givinostat is an orally administered histone deacetylase (HDAC) inhibitor developed by Italfarmaco for the treatment of Duchenne muscular dystrophy (DMD). The drug modulates the expression of genes involved in inflammation, fibrosis, and muscle regeneration by inhibiting HDAC activity, thereby helping preserve muscle tissue and slow disease progression. In March 2024, givinostat received approval from the U.S. Food and Drug Administration for the treatment of DMD in patients aged 6 years and older, regardless of the underlying dystrophin gene mutation, making it the first non-steroidal therapy approved to address the disease’s underlying pathogenic mechanisms. Clinical studies demonstrated that givinostat significantly slowed the decline in motor function compared with placebo while exhibiting a manageable safety profile, with common adverse events including thrombocytopenia, diarrhea, abdominal pain, and hypertriglyceridemia that require routine monitoring. As an oral therapy that can be used alongside standard corticosteroid treatment, givinostat represents an important advance in DMD management by targeting disease progression rather than solely alleviating symptoms. The report provides Givinostat’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Givinostat Market Report

The report provides insights into:

• A comprehensive product overview including the Givinostat MoA, description, dosage and administration, research and development activities in approved indications like Duchenne muscular dystrophy; as well as potential indication like Polycythaemia vera and Myeloproliferative disorders.
• Elaborated details on Givinostat regulatory milestones and other development activities have been provided in Givinostat market report.
• The report also highlights Givinostat‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Givinostat market report also covers the patents information, generic entry and impact on cost cut.
• The Givinostat market report contains current and forecasted Givinostat sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Givinostat market report also features the SWOT analysis with analyst views for Givinostat in approved and potential indications.

Methodology

The Givinostat market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Givinostat Analytical Perspective by DelveInsight

• In-depth Givinostat Market Assessment

This Givinostat sales market forecast report provides a detailed market assessment of Givinostat for approved indication like Duchenne muscular dystrophy; as well as potential indication like Polycythaemia vera and Myeloproliferative disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Givinostat sales data uptil 2034.

• Givinostat Clinical Assessment

The Givinostat market report provides the clinical trials information of Givinostat for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Givinostat Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Givinostat Market Potential & Revenue Forecast

• Projected market size for the Givinostat and its key indications
• Estimated Givinostat sales potential (Givinostat peak sales forecasts)
• Givinostat Pricing strategies and reimbursement landscape

Givinostat Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Givinostat Market positioning compared to existing treatments
• Givinostat Strengths & weaknesses relative to competitors

Givinostat Regulatory & Commercial Milestones

• Givinostat Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Givinostat Clinical Differentiation

• Givinostat Efficacy & safety advantages over existing drugs
• Givinostat Unique selling points

Givinostat Market Report Highlights

• In the coming years, the Givinostat market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Givinostat companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Givinostat’s dominance.
• Other emerging products for Duchenne muscular dystrophy; as well as potential indication like Polycythaemia vera and Myeloproliferative disorders are expected to give tough market competition to Givinostat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Givinostat in approved and potential indications.
• Analyse Givinostat cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Givinostat sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Givinostat in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Givinostat? How strong is Givinostat’s clinical and commercial performance?
• What is Givinostat’s clinical trial status in each individual indications such as Duchenne muscular dystrophy; as well as potential indication like Polycythaemia vera and Myeloproliferative disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Givinostat Manufacturers?
• What are the key designations that have been granted to Givinostat for approved and potential indications? How are they going to impact Givinostat’s penetration in various geographies?
• What is the current and forecasted Givinostat market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Givinostat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Givinostat for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Givinostat? What is the duration of therapy and what are the geographical variations in cost per patient?